Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET

Company Participants

Corey Davis - LifeSci Advisors

Scott Struthers - Founder and Chief Executive Officer

Alan Krasner - Chief Endocrinologist

Marc Wilson - Chief Financial Officer

Jim Hassard - Chief Commercial Officer

Conference Call Participants

Joseph Schwartz - Leerink Partners

Yasmeen Rahimi - Piper Sandler

Jeff Hung - Morgan Stanley

Cory Jubinville - LifeSci

Brian Skorney - Baird

Douglas Tsao - H.C. Wainwright

Jon Wolleben - Citizens JMP

Yuchen Ding - Jefferies

Leland Gershell - Oppenheimer

Operator

Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2023 Financial Results Conference Call. At this time all participants are in listen-only mode. Following the management's prepared remarks, we will hold a question-and-answer session.

I will now turn the call over to Corey Davis of LifeSci Advisors. Please go ahead.

Corey Davis

Thank you, Sergio, and hello everyone. Joining me on the call today are Scott Struthers, Founder and Chief Executive Officer; Alan Krasner, Chief Endocrinologist; and Mark Wilson, Chief Financial Officer. Also joining us for the Q&A portion of the call are Dana Pizzuti, Chief Medical and Development Officer, and Jim Hassard, Chief Commercial Officer.

A press release announcing the fourth quarter and full-year 2023 financial results was issued today and is also available on the Crinetics website. As a reminder, we'll be making forward-looking statements and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance and the company's actual results could differ materially from those stated or implied such statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release. The company's other news releases, and Crinetics SEC filings, including its annual report on Form 10-K.

I'd also like to specify that the content of this conference call contains time-sensitive information that is accurate, only as the date of this live broadcast February 28, 2024. Crinetics takes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.

I'll now hand the call over to Scott Struthers. Scott, go ahead.

Scott Struthers

Thanks, Corey. Good afternoon, everyone, and thank you for joining us for our quarterly results call. As the company progresses towards commercialization, it's our intent to expand our investor outreach and provide regular opportunities for interactive dialogue. We appreciate your attendance and look forward to our discussion today and on future quarterly calls.